For patients with severe obesity-related complications, providers may lean toward therapies with the strongest efficacy data currently available
Keep track of your readings to spot trends and share them with your doctor at regular check-ups
Patients with type 2 diabetes, insulin resistance, or those looking to lose a significant amount of weight are often good candidates for the program
It mimics the action of glucagon-like peptide-1 (GLP-1), stimulating insulin release, suppressing glucagon secretion, and slowing gastric emptying
There may be a brief plateau or minor fluctuation during the early low-dose period of semaglutide, but this is typically temporary
Many patients do not realize that weight-loss medications require special perioperative consideration, so explicit disclosure is critical even if not directly asked